The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Incremental cost (IC) analysis of skeletal related events (SREs) among elderly men with stage IV metastatic (M1) prostate cancer (PCa).
Jinani Jayasekera
No relevant relationships to disclose
Ebere Onukwugha
Consultant or Advisory Role - Janssen
Research Funding - Bayer; Novartis; Pfizer; Sanofi
Kaloyan A. Bikov
Research Funding - Bayer
C. Daniel Mullins
Consultant or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Honoraria - Bayer; Celgene; Pfizer
Research Funding - Amgen; Bayer; Pfizer
Brian S. Seal
Employment or Leadership Position - Bayer
Arif Hussain
Research Funding - Amgen; Bayer